About

Over the past decades, my laboratory and I have been interested in how to harness or enhance the immune system to treat disease. Our first studies evaluated why acute GvHD after allogeneic bone marrow transplant involved a specific number of organs regardless of the degree of MHC mismatch. We demonstrated a critical role for chemokine receptors and ligands in the trafficking of immune cells after transplantation and that GvHD occurred at sites with antigen presenting cells that were activated by pathogen associated molecular molecular patterns. Our most recent work has focused on the role of B lymphocytes in the anti-tumor immune response and characterizing antibodies generated by tumor-associated B cells. Finally, we have developed novel approaches to enhance adoptive cellular therapy (ACT) of solid tumors by activating the STING pathway during the administration of ACT.